Navigation

Juvenile idiopathic arthritis (systemic) - canakinumab [ID533]

Canakinumab for the treatment of systemic juvenile idiopathic arthritis

Status: History
Expected date of issue: TBC
Referral date: May 2012
Process: STA
Notes:

Scoped as part of Batch 22

Topic area:
  • Musculoskeletal
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
27 November 2013 TA302 Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) published
25 October 2013 The manufacturer of Canakinumab has informed NICE that they will not provide a submission for this appraisal. NICE has therefore suspended this appraisal.
24 July Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.
Top


 

Key documents

This page was last updated: 25 November 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.